For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
— New weight loss drugs like Ozempic, Wegovy and Zepbound
may make oral birth control pills less effective at certain points —
SAN DIEGO, March 7, 2024 /PRNewswire/ — Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.
Related news for (EVFM)
- FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences’ “One and Done” Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Evofem Biosciences to Present at Emerging Growth Conference
- Windtree Therapeutics Strikes Deal to Source PHEXXI, Signaling Revenue-Driven Pivot
- Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
- Evofem Biosciences Announces Financial Results for the Second Quarter of 2024